DIAGENS-B (02526) has officially been included in the Stock Connect, opening up a channel for mainland investors to participate.

On September 4, the Shanghai Stock Exchange issued a notice stating that, according to the relevant provisions of the "Implementation Measures for the Shanghai-Hong Kong Stock Connect," DIAGENS-B (02526) has been officially added to the list of eligible securities for the Hong Kong Stock Connect. This adjustment will take effect on September 7 (Monday). This means that mainland investors can now directly buy and sell DEAGENS through the Shanghai-Hong Kong Stock Connect, effectively unlocking southbound capital. On September 2, DEAGENS and The Hong Kong Polytechnic University officially unveiled the "PolyU-DEAGENS Joint Laboratory for General Artificial Intelligence and Medical Applications." The two parties will conduct long-term research collaboration focusing on medical imaging analysis, the construction of large foundational models for healthcare, and the automation of medical R&D processes, promoting the transformation of AI for Science within the medical field and facilitating the connection of research achievements with innovation networks in mainland China, Hong Kong, and even globally.